Mirum Pharmaceuticals (MIRM) Interest & Investment Income (2019 - 2026)

Mirum Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 12.5% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $13.1 million, a 0.58% decrease from a year earlier, with the FY2025 full-year figure at $12.7 million, down 7.72% from the prior year.
• Interest & Investment Income declined to $3.4 million in Q1 2026 per MIRM's latest filing, from $3.4 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.1 million in Q3 2023 and bottomed at $69000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $3.3 million (2025), against an average of $2.8 million.
• Biggest YoY gain for Interest & Investment Income was 3196.92% in 2022; the steepest drop was 53.69% in 2022.
• Year by year, Interest & Investment Income stood at $2.1 million in 2022, then soared by 76.15% to $3.8 million in 2023, then slipped by 15.13% to $3.2 million in 2024, then gained by 6.74% to $3.4 million in 2025, then fell by 0.56% to $3.4 million in 2026.
• Per Business Quant, the three latest MIRM Interest & Investment Income figures stand at $3.4 million (Q1 2026), $3.4 million (Q4 2025), and $3.3 million (Q3 2025).